Piper Jaffray hired Tyler Van Buren as a senior research analyst in its equity research group. Based in New York, he will be responsible for covering biotechnology companies.
“Tyler brings a breadth of both industry and sell-side experience across biopharma, biotech and the broader healthcare space. This addition will add strength to our firm’s overall leadership in the healthcare sector and add immediate value for our clients,” said Michael Cox, director of equity research at Piper Jaffray.
Van Buren joined Piper Jaffray from Cowen, where he was an equity research analyst covering biopharma companies for five years. Prior to that, he was a co-founder and managing director at New York-based LifeSci Advisors, where he helped build the firm’s biotechnology research practice. Van Buren also worked in various roles at Amylin Pharmaceuticals, Lithera Pharmaceuticals, the Sanford-Burnham Medical Research Institute and the U.S. Department of Agriculture.
The Piper Jaffray equity research group consists of 40 senior analysts covering 680 companies across the following sectors: consumer, energy, financial services, healthcare, industrials and business services, and technology.
